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1. Introduction  
Portal hypertension is the commonest cause of upper gastrointestinal bleeding in children and 
up to 30% of cases with upper gastrointestinal hemorrhage can be fatal. Extrahepatic portal 
venous obstruction (EHPVO) is the commonest cause of portal hypertension in children and 
also one of the common causes in adults in India and other tropical countries (Arora, 1998; 
Poddar, 2008; Poddar 2000). In India, EHPVO is responsible for portal hypertension in about 
one third cases of adults and more than half of the cases in children (Sarin 2002; Dilawari 
1992). EHPVO is characteristically refers to obstruction in the trunk of portal vein and it can 
extend to its branches and even splanchnic veins. Unlike cirrhosis, in EHPVO, the liver 
function is normal. The causes of portal venous obstruction and risk factors for upper 
gastrointestinal hemorrhage in children with EHPVO are not clearly understood. Most of the 
bleeds are spontaneous and some may be preceded by febrile illness, ingestion of drugs. 
Management of EHPVO involves acute management of the bleeding, secondary prophylaxis 
and shunting to reduce the portal pressure. This chapter attempts to compile the available 
evidences on EHPVO in children with special reference to experiences from India.  
2. Definitions and terminology  
EHPVO indicates portal hypertension due to blockage in the portal vein before the blood 
reaches the liver. EHPVO is a distinct disease entity of primarily vascular in nature and not 
classically associated with association of a primary liver disease. Portal vein thrombosis, a 
known complication of liver cirrhosis, other systemic diseases and malignancy, is not generally 
included in the disease entity EHPVO. Over time, EHPVO terminology has replaced the use of 
portal vein thrombosis (PVT) as it does not exclude the intrahepatic portal vein thrombosis 
and does not include formation of portal cavernoma associated with portal hypertension.  
Baveno V workshop consensus statement defined EHPVO as (De Franchis, 2010):  
 EHPVO is defined by obstruction of the extra-hepatic portal vein with or without 
involvement of the intra-hepatic portal veins and does not include isolated thrombosis 
of splenic vein or superior mesenteric vein (SMV).  
 EHPVO is characterized by features of recent thrombosis or of portal hypertension with 
portal cavernoma as a sequel of portal vein obstruction 
 Presence of cirrhosis and/or malignancy should be stated.  
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3. Epidemiology  
EHPVO is a common cause of portal hypertension in the developing countries (30-55% of all 
variceal bleeders) and is second to cirrhosis (up to 5-13%) (Arora, 1998; Valla, 2002). EHPVO 
is also the most common cause of upper gastrointestinal bleeding in children. It accounts for 
almost 70% of pediatric patients with portal hypertension (Yachha, 1996; Arora, 1998). 
Literature from different parts of India indicated that in children EHPVO is responsible for 
54% of portal hypertension (Poddar, 2008). Most (85-92%) of the upper gastrointestinal 
bleeding in Indian children was result of portal hypertension due to EHPVO (Poddar, 2008; 
Yachha, 1996). 
Investigators across India have consistently observed that EHPVO occurs commonly in 
children belonging to low and lower middle socio-economic strata attending public sector 
hospitals. Pediatric gastroenterologists practicing in private sector hospitals see such 
patients infrequently. During last 10-15 years, the number of EHPVO patients gradually 
appears to be dwindling even in public sector hospitals. Thus it appears that the disease 
may have something to do with the living condition of the families and with improving 
economic state of the families, disease may become less frequent.  
4. Etiology and pathogenesis  
4.1 Etiology 
The etiology of EHPVO in children has not been well documented. There are many etiologies 
for EHPVO namely infections, surgical procedures, vascular interventions, abdominal trauma, 
dehydration, congenital anomalies have been postulated. EHPVO is considered to be 
heterogenous with regard to etiology and pathogenesis, and vary with respect to age and 
geographical location. The causes can broadly be of five types; infection and inflammation, 
portal vein injury, developmental anomaly, prothrombotic causes and idiopathic.  
4.1.1 Infection 
Omphalitis, neonatal umbilical sepsis, intraabdominal infection, post umbilical 
catheterization have been linked to development of EHPVO in children. Although it is 
documented that portal vein thrombosis may occurs in neonates having umbilical vein 
catheterization, but most of these thrombi resolve within a short period (Larroche, 1970; 
Thompson, 1964). It is also proposed that phlebosclerosis is primary as a result of infection 
and/or and inflammation followed by thrombosis as a secondary event (Stringer, 1994). But 
evidence on this linkage is not very strong in children with EHPVO.  
4.1.2 Trauma and surgery 
Umbilical vein cannulation, abdominal surgery, and abdominal trauma in childhood could 
also lead to EHPVO (Yadav, 1993). 
4.1.3 Congenital anomaly 
Congenital defects like web, valves in the portal vein, portal vein stenosis, atresia or 
agenesis have also been reported (Odievre, 1977). There may be presence of other 
cardiovascular system congenital defects.  
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4.1.4 Prothrombotic state 
Hypercoagulable states like deficiencies of antithrombotic factors (protein-C, protein-S, anti-
thrombin III) have been reported in children with EHPVO (Bhattacharya, 2004; Pinto, 2004; 
Koshy, 1984; Dubuisson, 1997). Absence of genetic mutations in EHPVO patients and 
normal levels of antithrombotic factors in their parents suggested that the deficiency of 
antithrombotic factors may not be primarily of genetic origin, but may be secondary to the 
low hepatic blood flow due to portal vein thrombosis (low synthesis) and portosystemic 
shunt (increased clearance or consumption) (Dubuisson, 1997; Sharma, 2006). Other 
conditions like polycythemia vera, dehydration have also been proposed as the causes of 
EHPVO.  
4.1.5 Idiopathic 
Despite all efforts, the etiology of blocked portal vein remains obscure in a large proportion 
of patients. In India the majority of cases (up to 90%) are categorized as idiopathic (Poddar, 
2003). Probably this is due to want of detailed etiological work-up.  
4.2 Pathogenesis  
4.2.1 Portal vein changes 
In EHPVO, usually the entire length of the portal vein is occluded with extension into the 
splenic vein and sometimes into the superior mesenteric vein. In small proportions only the 
terminus of the portal vein at the hilum is occluded. Mostly the site of blockage is at the 
portal vein formation and in small proportions the total splenoportal axis is blocked. In a 
report by our group among Indian children with EHPVO (n=88), blockage were observed at 
portal vein formation, entire portal vein, spleninc vein and entire splenoportal axis in 39%, 
34%, 16% and 11% respectively (Arora, 2002). On gross examination, the original portal vein 
is difficult to identify as it is usually replaced by a cluster of variable-sized vessels arranged 
haphazardly within a connective tissue support, called as the portal cavernoma. In cases of 
shorter duration, cavernoma may not be there. The porto-systemic collaterals develop over 
time leading to development of verices at different places in the gastrointestinal tract, and at 
other places depending on the portal venous pressure and duration.  
In EHPVO the blockage being presinusoidal, intrahepatic venous pressure is normal and 
intrasplenic pressure is increased. The hepatic blood flow is relatively normal as the 
portoportal collateral vessels enable bypassing the blocked area. The hepatic blood flow 
may be reduced if the collaterals are not enough. EHPVO is a hyperkinetic circulatory state 
with increased cardiac output as a result of extensive porto-systemic venous collaterals.   
4.2.2 Liver changes 
Classically, in EHPVO cases liver is normal and the architectural pattern is preserved. 
Histopathology may reveal concentric condensation of reticulin fibers around portal tracts, 
sometimes extending into the parenchyma. Altered hepatic storage capacity and transport 
maximum for bromsulphalin and liodocaine (MEGX) excretion has been reported in 
EHPVO. Usually liver biopsy is not required in EHPVO cases, unless liver functions are 
deranged.  
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5. Clinical presentations  
In children, EHPVO may manifest at any age beyond the neonatal period. EHPVO can 
present in two clinical forms: recent or acute and chronic. The clinical presentation also 
differs in children and adults.  
5.1 Recent or acute EHPVO 
This can present with abdominal pain, ascites or fever. This may, however, be asymptomatic 
and go unnoticed. In recent EHPVO, there is no evidence of porto-systemic collaterals and 
portal cavernoma. The extent of obstruction in portal vein and speed of evolution of 
thrombosis predicts the clinical manifestation. If associated with infection, features of sepsis 
may be there. But many a times these may be passed as episodes of acute abdomen or 
sepsis.  
5.2 Chronic EHPVO 
Most of the EHPVO present as chronic cases with the typical presenting symptoms like 
episodes of variceal or gastrointestinal bleeding, lump in the abdomen and hypersplenism.  
EHPVO in childhood is most often chronic and presents with features of variceal bleeding 
and splenomegaly, whereas in adults it could be either acute or chronic.  
5.2.1 Variceal bleeding 
Esophageal varices are the most common site of variceal bleeding. The majority of children 
(85% to 90%) with EHPVO present with variceal bleeding (Arora, 1998; Poddar, 2008; Valla, 
2002). The usual presentation for children with EHPVO is sudden, unexpected and, often, 
massive hemetemesis. Bleeding usually occurs in first or second decade of life. Some of the 
children also present with recurrent, well-tolerated bleeds with variable degree of anemia. 
There is no significant hepatocellular failure in these patients. Although many clinicians think 
that the frequency of variceal bleeding reduces after puberty, but this has not been confirmed. 
Gastic varices are common in EHPVO. According to reports, about 70% children at 
diagnosis have gastric varices. Most of these are gastroesophageal varices while a few are 
isolated gastric varices (Sarin, 1992; Arora, 1998; Poddar, 2004). Following eradication of 
esophageal varices, gastric varices become more evident with increase in risk of bleeding 
(Poddar, 2004; Goncalves, 2000).  
Rectal varices are documented in 80-90% of adult EHPVO cases (Misra, 2005). The scanty data 
in children indicate presence of rectal varices in 36-64% (Heaton, 1993; Yachha, 1996). It also 
probably related to the severity and duration of portal hypertension or site of obstruction (at 
the junction of splenic and superior mesenteric veins leading to redistribution of portal 
pressure along the inferior mesenteric vein) (Misra, 2005; Chawla, 1991; Ganguly, 1995). 
Appearance of these varices may increase after obliteration of the esophageal varices.  
5.2.1.1 Risk factors for bleeding and rebleeding after initial sclerotherapy 
Bleeding from varices occurs usually due to erosion or rupture of variceal vessel wall. 
Bleeding due to erosion of vericeal wall is precipitated by reflux esophagitis, drug ingestion 
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(NSAIDs), and febrile illness (Yadav, 1993; Arora, 2002; Lilly, 1982). Size of varix, vessel wall 
thickness and tissue support also determine the chance of variceal bleeding. Considerable 
agreement exists regarding the relationship of variceal size to the risk of bleeding. Large 
variceal size appears to predict bleeding (Rector, 1985). Incomplete variceal obliteration has 
also been suggested as risk factor for rebleeding (Kokawa, 1993). Vessel wall thickness and 
tissue support are difficult to assess by endoscopy, but reddish-blue tense varices that are 
not obliterated on insufflations and congestive mucosa on and around the varices (cherry 
red spots) are likely to bleed (Alvarez, 1983). Evidence relating to risk of variceal 
hemorrhage secondary to raised portal pressure is inconclusive.  
Our group at AIIMS, New Delhi followed 58 children with EHPVO (age group: 5 months-
158 months) who underwent endoscopic sclerotherapy (EST) for a median period of 20.5 
months (17-31 months). About half of the patients (28 children) had one or more bleeding 
episodes (total 88 bleeding episodes) during the follow up period, out of which 21 patients 
had minor and 7 patients had major bleeding episodes. Congestive gastropathy was 
observed in all of these patients. The median time interval of occurrence of the any rebleed 
after completion of EST was 3.5 months [95% CI = 2-7]. Kaplan Meier Survival Analysis 
indicated that 50 % of patients [95% CI: 34.9 - 63.5%] had first rebleeding episode by 27 
months and most of these patients had recurrence of bleeding within 12 months. The 
relative risks of rebleeding due to risk factors were 2.37 (95% CI = 1.36 - 3.85), 8.9 (95% CI = 
2.4 - 23) and 6.1 (95% CI = 3.3 - 10.4) for fever alone, NSAID drug (Ibuprofen and 
Paracetamol) intake alone and when both fever and drug ingestion respectively. There was 
no significant difference in the nutritional status of these patients at the end of this follow up 
period (Arora, 2000).  
5.2.2 Mass abdomen 
About 10% of the children present with isolated abdominal mass due to splenomegaly 
(Arora, 1998; Mittal, 1994). EHPVO is associated with splenomagaly and size of spleen 
usually increases with age and it may even reach the right iliac fossa. Massive splenomegaly 
may result in anemia and thrombocytopenia due to hypersplenism in about 1/3rd of cases. 
In cases of acute variceal bleeding, the spleen size may reduce temporarily and reappear on 
hemodynamic stabilization. 
5.2.3 Pain abdomen 
Dull abdominal pain may be there due to the splenmegaly. Presence of continuous abdominal 
pain may indicate splenic infarction or extension of venous thrombosis (Yachha, 1996). 
5.2.4 Ascites and edema 
Ascites may develop in a proportion of children following hemorrhage or surgery, and are 
often transient. Ascites have been reported in up to one fifth of children with EHPVO 
(Webb, 1979; Rangari, 2003). Development of ascites signifies and circulatory changes. Some 
patients may also have pedal edema. Some children with EHPVO develop intractable ascites 
with no evidence of hepatic dysfunction. These patients are likely to benefit from large 
peritoneal drainage or may require shunt surgery. In all cases of ascites, hepatic dysfunction 
must be carefully looked for.  
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5.2.5 Ectopic varices 
These have been reported in 27-40% of patients with EHPVO, and are commonly seen in the 
duodenum, anorectal region and gallbladder bed (Sarin, 2006). Bleeding from the varices in 
duodenum and anorectal regions are not uncommon.  
5.2.6 Jaundice 
Jaundice is rarely a presenting feature of EHPVO and is generally due to portal biliopathy or 
stricture of bile duct in longstanding cases.  
5.3 Complications and sequelae of EHPVO 
EHPVO is associated with several complications and sequalae those need mention from the 
clinical manifestation and management point of views. The documented sequelae observed 
in long course of EHPVO are as follows.  
5.3.1 Portal biliopathy 
Portal biliopathy refers to abnormalities of the extrahepatic and intrahepatic bile ducts in 
patients with portal hypertension. These include compression by paracholedochal collaterals 
on bile ducts resulting in displacement, narrowing, strictures, angulation, dilatations and 
irregularity of bile ducts. Extrinsic compression, ischemia, and a combination of both have 
been proposed as the possible mechanisms for this. Although portal biliopathy features have 
been reported in 80-100% of adult patients with EHPVO on endoscopic retrograde cholangio-
pancreatography (ERCP), up to one fifth are symptomatic (Dilawari, 1992; Khuroo, 1993; 
Malkan, 1999; Nagi, 2000; Poddar, 2001). These changes may become severe enough to cause 
obstructive jaundice and choledocholithiasis and cholelithiasis due to bile stasis. 
Cholangiographic changes are also evident in children with EHPVO, but mostly symptomatic 
in adulthood (Poddar, 2011). Although, biliary abnormalities are common in portal 
hypertension, only a few patients present with jaundice, pain and cholangitis. 
Choleodocholithiasis has been reported to occur in 17% of patients with portal biliopathy 
(Bhatia, 1995). ERCP is the definitive method for diagnosis of biliopathy. MRCP is a good non-
invasive alternative to ERCP. However, as the majority of patients with biliopathy are 
asymptomatic, ERCP is recommended only if a therapeutic intervention is contemplated. 
5.3.2 Ectopic varices 
Gall bladder varices are observed in 34% of adult patients with EHPVO (Chawla, 1995). 
Reports in children with EHPVO are scanty. Presence of portal vein thrombosis is an 
important determinant for the development of gall bladder varices. Rectal varices may be 
seen in up to 80% of patients with EHPVO and the development is related to the duration. 
These varices may also bleed profusely (Sarin, 1992). Gall bladder varices are reported in 12-
30% of adults with EHPVO (Chawla, 1995; West, 1991). 
5.3.3 Gastropathy and colopathy 
Gastropathy and colopathy represent congested mucosa at different parts of gastrointestinal 
tract which may present as occult gastrointestinal bleeding, but sometimes also as overt 
www.intechopen.com
 
Extra Hepatic Portal Venous Obstruction in Children 
 
47 
bleeding. About one fourth of the EHPVO children have gastropathy at presentation, but 
the prevalence increases significantly (2 times or more) after variceal eradication (Hyams, 
1993; Poddar, 2004). Portal colopathy may be seen in up to half of the patients with EHPVO 
(Sarin, 1992; Arora, 1999).  
5.3.4 Hyersplenism 
Massive splenomegaly may cause pooling and excessive destruction of the pooled blood cell 
components leading to thrombocytopenia, leucopenia and anemia. It can also predispose to 
infection and or bleeding. The hypersplenism does not correlate with splenic size. Splenic 
sequestration crisis may occur leading to hypovolemic shock and death. 
6. Specific issues in children  
6.1 Growth retardation 
EHPVO in children often reported to be associated with growth retardation.  
Reports from India indicated that the majority of the Indian children with EHPVO were 
stunted compared to the national control or to the National Center for Health Statistics 
(USA) reference (Mehrotra, 1997; Sarin, 2002; Arora, 2000). It also appears that the lean mass 
building is more likely to be affected than the fat storage (Mehrotra, 1997). Although the 
growth velocity have not been documented in any of these studies but the Z scores for 
height and weight at diagnosis and during follow-up after sclerotherapy were not 
statistically different. One study from India reported lower growth velocity in majority of 
children with EHPVO compared to the controls despite adequate nutrition (Sarin, 1992). A 
report from Brazil (n= 24; median age 5.9 years) reported that children with EHPVO had 
adequate growth for the age at diagnosis and over follow up period of 3.8±2.5 years 
compared to the NCHS reference (Bellomo-Brandao, 2003). Although the exact mechanism 
of the growth failure is not known, the following possible mechanisms have been proposed.  
- Poor substrate utilization or/and malabsorption due to portal hypertensive enteropathy 
is the proposed mechanism. This is supported by improved growth in many children 
with EHPVO after shunt surgery (Menon, 2005).  
- Impaired synthesis of growth factors due to shunting of blood away from the liver is 
another hypothesis . Significantly increased levels of growth hormone and decreased 
levels of insulin-like growth factor-1 (IGF-1) and insulin-like growth factor binding 
protein-3 (IGFBP-3) have been noted in EHPVO patients, suggesting growth hormone 
resistance (Mehrotra, 1997; Nihal, 2009). It is proposed that reduced portal blood flow 
results in decreased insulin reaching the liver and thereby decreased production of IGF-
I and IGFBP-3. Shunt surgery, mesenterico-left portal vein bypass (MLPVB) with 
improvement in growth parameters in children with EHPVO supports this hypothesis 
(Lautz, 2009; Stringer, 2007).  
- Frequency of bleeding has been linked to the growth in these children. It is observed 
that children with frequent bleeding have severe growth retardation while children 
with asymptomatic course are normal or near normal (Mowat, 1987). 
While growth parameters in children with EHPVO have shown improvement after shunt 
surgery, no change in growth trend were documented in children after sclerotherapy 
(Arora, 2000; Sarin, 2002), even with adequate caloric intake (Sarin, 1992). This also support 
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the proposed substrate metabolism, insulin and growth factor mediated mechanisms as the 
cause of growth failure. The overall nutritional status and underlying etiology and the 
associated complications of recurrent bleeds may influence the growth in children with 
EHPVO.  
6.2 Mental function and encephalopathy 
Mild cognitive and psychomotor deficit has been reported in patients with EHPVO in 
absence of liver disease (Sarin, 2006). Hyperammonia as a result of porto-systemic shunting 
in EHPVO may lead to generalized low grade cerebral edema. Abnormal cognitive 
functions may be evident on neuropsychological tests in some of these patients with 
apparently normal neurological status, which is described as having minimal hepatic 
encephalopathy. Normal liver functions probably reduce the severity of hepatic 
encephalopathy. A term type B hepatic encephalopathy has been proposed for this 
condition (Ferenci, 1998). In a recent Indian series of children, about one-third of children 
with EHPVO had abnormal neuropsychological test findings (visual-motor coordination 
and spatial orientation), raised blood ammonia, abnormal MRI signal, and abnormal brain 
metabolites on MR spectroscopy compared to the normal children (Yadav, 2010).  
7. Diagnosis and investigation findings  
A child with upper gastrointestinal bleeding (manifesting as either hematemesis and/or 
malena) and splenomegaly but no features of chronic liver disease is likely to be suffering 
from EHPVO. Normal liver function test and absence of virologic markers in a child with 
portal hypertension further suggest towards EHPVO. But the other causes of non-cirrhotic 
portal hypertension and compensated childhood cirrhosis are to be excluded. Imaging of 
spleno-portal axis is the mainstay for the diagnosis of EHPVO. According to Baveno V 
consensus statement, EHPVO is diagnosed by Doppler US, CT, or MRI, which demonstrate 
portal vein obstruction, presence of intraluminal material or portal vein cavernoma. Recent 
EHPVO is characterized by demonstrated portal venous obstruction without cavernoma (De 
Franchis, 2010).  
7.1 Ultrasonography 
Ultrasound (US) is a reliable non-invasive diagnostic tool with a high degree of accuracy for 
the detection of blockage in splenoportal axis and portal portal cavernoma, and is the 
investigation of choice (Sharma, 1997). Usually the normal portal vein and branches are 
invisible and are replaced by multiple tortuous collateral veins with hepatopetal flow, the 
cavernomatous transformation of the portal vein. Large collateral vein may simulate to be 
portal vein but tortuosity and presence of surrounding small channels help in 
differentiation. Portal vein thrombus may be observed as an echogenic lesion within the 
vessel, although a recently formed thrombus may be anechoic. Colour Doppler imaging is 
very helpful in detecting portal vein flow and diagnosing portal vein obstruction, spleno-
portal collaterals and shunts with sensitivity of 70 - 90% and specificity of 99% (Nyandak, 
2011). Ultrasound may also indicate about the liver pathology (size and echogenicity) and 
portal biliopathy which may have intrahepatic bile duct dilatation due to compression of the 
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common bile duct by the cavernoma. Endoscopic ultrasound (EUS) may further advance the 
diagnostic accuracy in patients with portal vein thrombosis.  
7.2 CECT 
In contrast-enhanced CT scan, thrombus may be seen as a nonenhanced intraluminal-filling 
defect. CECT has the advantage of displaying varices and parenchymal hepatic 
abnormalities also. The combination of CT scan and Doppler ultrasound is common in the 
evaluation of portal vein obstruction.  
7.3 MRI 
MRI and magnetic resonance angiography (MRA) are helpful for evaluating hepatic 
parenchymal details, to quantitate portal and hepatic vessel flow for planning of 
interventions, such as shunt surgery. MRI can help detecting and differentiating acute and 
old clots and blockage due to tumor thrombi. MRI and MRA are highly sensitive and 
specific for detecting both the thrombi and submucosal, serosal, paraoesophageal collaterals. 
CT and MRA may be more useful for detecting the recent EHPVO.  
7.4 Endoscopy 
Upper gastrointestinal endoscopy is must for all EHPVO patients to detect the status of 
varices, any site of bleeding and associated congestive gastropathy. For detecting the lower 
gastrointestinal bleeding due to rectal or colonic varices, lower gastrointestinal endoscopy 
may be needed.  
7.5 Biochemical tests 
Biochemical liver function test parameters are usually within normal range, unless 
associated with underlying liver disease. But with longstanding disease liver function may 
deteriorate. Viral markers for hepatotropic viruses are to be screened as these children are at 
high risk for blood borne transmission due to repeated blood transfusions. Liver biopsy is 
not indicated in EHPVO unless underlying liver pathology is suspected. Screening for 
prothrombotic disorders may help in identifying underlying coagulopathy.  
7.6 Radionuclide scan 
In cases of gastrointestinal bleeding not visualized by endoscopy may need radionuclide 
scanning (99m Technetium sulfur colloid and 99m technetium pertechnate labeled RBCs) to 
detect the site of bleeding if not evident on endoscopy. 99m Tc scan can even detect bleeding 
rate of 0.1–0.5 mL/min. Radionuclide scan is only rarely required.  
7.7 Additional tests 
Additional tests like ERCP and MRCP may be indicated to detect the presence of portal 
biliopathy, if suspected. Endoscopic retrograde cholangiopancreatography (ERCP) is 
indicated for confirming portal biliopathy, particularly if there are features of cholangitis or 
obstructive jaundice.  
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8. Management  
8.1 Concepts and principles of management 
Management of EHPVO depends on the age of the patient, the site of obstruction and the 
clinical presentation. Liver involvement necessitates modification in approach to 
management. Management in children also needs to address the nutrition to ensure optimal 
growth.  
8.2 Prophylaxis 
Prophylaxis is very important in cases with portal hypertension to reduce the risk of initial 
bleeding (primary prophylaxis) or rebleeding (secondary prophylaxis) through reducing the 
vascular pressure in splenoportal axis.  
8.2.1 Primary prophylaxis 
Evidence on the role of primary prophylaxis in the management of portal hypertension and 
portal hypertension has not been adequately studied in children. Use of Propranolol (1-
2mg/kg body weight/day) as primary prophylaxis has been shown to be effective in 
reducing bleeding compared to secondary prophylaxis (15.6% vs 53.3% respectively) 
(Ozsoylu, 2000). So, children with varices on endoscopy are to be initiated on beta blocker, 
but follow up endoscopy is to be done to check the status every 6-12 monthly interval. 
Prophylactic endoscopic sclerotherapy and variceal obliteration is also in practice. Use of 
prophylactic EST children with portal hypertension had lower bleeding episodes (24%) 
compared to controls (42%) over a median follow-up of 4.5 years (Goncalves, 2000). But the 
evidence and experience in children is limited to support recommendation of prophylactic 
EST or EVL.  
8.2.2 Secondary prophylaxis 
Evidences on secondary prophylaxis are better than that of primary prophylaxis. Beta 
blockers are in use for reducing portal pressure and thereby reducing risk or variceal 
bleeding. Propranolol is commonly used at dosage 2mg/kg body weight/day in 2 divided 
doses. Heart rate is monitored and dosage is adjusted to prevent fall of heart rate more than 
20% of baseline or absolute heart rate below 60/minute. Metaanalysis indicated the benefit 
of beta blocker in reducing variceal bleeding (Sarin, 1996). About 20% of the patients do not 
respond to the beta blockers and some cannot be given due to contraindications like 
congestive heart failures, peripheral vascular diseases, chronic obstructive pulmonary 
diseases, asthma, and insulin dependent diabetes mellitus.  
8.2.3 Management of gastrointestinal bleeding 
Gastrointestinal bleeding related to portal hypertension and EHPVO may be of variceal or 
mucosal in nature. Variceal bleeding may be of acute nature presenting as life threatening 
episode or of chronic with recurrent episodes or malena with or without anemia. Usually 
acute variceal bleedings are life threatening with sudden onset and may be associated with 
loss of large volumes of blood. It can be fatal in 30-40% of cases.  
www.intechopen.com
 
Extra Hepatic Portal Venous Obstruction in Children 
 
51 
Quick history and clinical examination is to be done to rule out non-GI bleeding, assess the 
severity of bleeding and hemodynamic status. There is no controversy about the 
management of acute variceal bleeding and involves the following five steps. 
i. Emergency resuscitation and hemodynamic stabilisation    
ii. Identification of source and site of bleeding  
iii. Stopping bleeding source   
iv. Monitoring  
v. Variceal obliteration  
While planning the management of acute bleeding, along with hemodynamic status, liver 
function status is also to be assessed as soon as possible to plan the management strategy. 
Urgent upper gastrointestinal endoscopy should be undertaken at the earliest after full 
resuscitation, to identify source and to intervene to stop bleeding.  
8.3 Endoscopic management of variceal bleeding  
8.3.1 Management of esophageal variceal bleeding 
Endoscopic variceal sclerotherapy (EST) and endoscopic variceal ligation (EVL) are two 
effective methods of controlling acute bleeding from esophageal varices. EST involved 
injection of sclerosant (sclerotherapy) into the varix and/or surrounding submucosa. 
Commonly used sclerosants ate sodium morruhate (1.5%), tetradecyl sulfate (0.5-1%), 
phenol (3%) and polidocanol (1%). EST is effective in eradicating esophageal varices in 88-
100% cases. However, complications like retrosternal pain (30-60%), fever (39%), ulcer (8% 
to 30%) and stricture (6% to 20%) are often encountered with EST (Poddar, 2011; Arora, 
2002). Meta-analysis of sclerotherapy in adults has demonstrated its advantage over 
vasopressin; and comparable efficacy with somatostatin or octreotide in controlling acute 
variceal bleeding (De Franchis, 1999). On the other hand endoscopic variceal ligation (EVL) 
involves ligation of the varix using bands. Although, EVL has the advantages of rapid 
eradication of varices requiring fewer sessions and portending fewer complications, use in 
younger children (< 2 years) may be an issue. Over the years, EVL has become the preferred 
mode of treatment of variceal bleeding in adults. However, the additional cost of banding is 
a constraint, especially in developing countries. The limited experience of EVL in children 
suggests its superiority over EST (Zargar, 2002).  
Newer endoscopic treatment modalities like thermal coagulation, electrocoagulation and 
laser photocoagulation are also being tried in adults. But the experience in children is not 
available.  
After initial control of bleeding, eradication of varices is necessary to prevent subsequent 
bleeding. Either EST or EVL in isolation or EST followed by EVL can be adopted for this. 
EVL alone although appears to be simpler and effective for initial eradication of varices, 
recurrence of varices is high, as obliteration of smaller varices and perforators is difficult. 
EST/EVL sessions are repeated at 1-2 weekly interval and usually 6-10 sessions are required 
to completely obliterate the esophageal varices. Variceal recurrence has been documented in 
40% of children after 2 years of EVL (McKiernan, 2002). So a combination of EVL and EST, 
initial EVL followed by low-dose EST appears to be more effective in children. It reduces the 
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sessions required, complications associated with large-dose EST for initial variceal 
eradication and the risk of variceal recurrence. Two studies from India supported this 
combination intervention (Poddar, 2005; Poddar, 2011).  
8.3.2 Management of gastric varices 
The experience in children is limited. Gastric varices bleed less frequently but when they do, 
they bleed profusely. Endoscopic injection of tissue adhesive agent (n-butyl 2 cyanoacrylate) 
has been effective in controlling such bleeding, as EST or EVL may not be suitable. Large 
gastric varices with or without bleeding are considered as an indication for shunt surgery.  
8.3.3 Management of colorectal varices 
Management of bleeding rectal varices include sclerotherapy or band ligation. For presence 
of larger rectal varices and colopathy with or without bleeding, shunt surgery may be 
considered.  
8.4 Medical management of variceal bleeding 
Several drugs are also used to reduce the portal venous pressure and thereby variceal 
bleeding before undertaking endoscopic therapy. These agents enable stabilization of the 
patient till the definite interventions are done or if not possible.  
8.4.1 Vasopressin 
Vasopressin is the most potent splanchnic vasoconstrictor. It reduces blood flow to all 
splanchnic organs, decreasing portal venous inflow and thereby decreasing portal pressure. 
Vasopressin is administered as continuous infusion and increased till maximum dosage is 
reached in titration with the bleeding. The infusion is to be continued for at least 24-48 hours 
after stoppage of bleeding. In about 60% of the patients bleeding is controlled using this 
agent (Tuggle, 1988). Although this drug in adults has been shown to control bleeding yet 
the mortality does not decrease and dose at highest level may be associated with 
complications. The usage is limited by adverse effects related to vasoconstriction in 
splanchnic bed leading to bowel ischemia and systemic circulation resulting in hypertension 
and myocardial ischemia. To minimize the systemic adverse effects, vasopressin should 
always be accompanied by intravenous nitroglycerin.  
8.4.2 Terlipressin 
Terlipressin is a synthetic analogue of vasopressin with longer biological activity and 
significantly fewer adverse effects. Terlipressin may have more sustained hemodynamic 
effects in patients with bleeding varices.  
8.4.3 Somatostatin 
Natural hormone somatostatin decreases portal pressure by causing splanchnic 
vasoconstriction. It is associated with lesser side effects compared to vasopressin. There is 
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limited experience in children. In adult patients somatostatin is effective in 64-92% cases 
(Burroughs, 1990). Blood sugar is to be monitored every 6 hourly to detect hypoglycemia.  
8.4.4 Octreotide 
It is a synthetic analogue of somatostatin and effective in controlling acute variceal bleeding 
in most (84-95%) of adult patients. It can be given as infusion or intermittent subcutaneous 
injections. Monitoring is similar to Somatostatin.  
There are limited data on the use of pharmacological agents for the control of acute bleeding 
in children with EHPVO. However, if EHPVO is due to acute thrombophilia, there is a 
theoretical risk of a decrease in splanchnic blood flow induced by bleeding and by 
therapeutic vasconstrictive agents that may cause extension of thrombus in the portal 
venous system resulting in intestinal ischemia.  
8.5 Other interventions to manage acute variceal bleeding  
8.5.1 Balloon tamponade 
Direct compression of varices with balloon (Sengstaken-Blackemore tube) has been used to 
stop bleeding. The smaller tube is also available for pediatric use. It has two balloons, one 
each for esophageal and gastric compression and one lumen for aspiration of gastric 
contents. The balloons are inflated using air or saline to compresses the varices at 
gastroesophageal junction and in esophagus. Intermittent deflation of the balloon is 
important to prevent mucosal ischemia. Aspiration is another complication that can 
potentially be fatal. This balloon device can control acute variceal bleeding up to 80% of 
cases (Pitcher, 1971; Brodoff, 1980). Positioning of the tube and is to be confirmed with plain 
X-ray abdomen. Selection of appropriate tube size, experience and following simple 
precautions are necessary to prevent tissue necrosis and aspiration.  
8.5.2 Transjugular Intrahepatic Portosystemic Shunt (TIPS) 
This procedure involves creation of an artificial shunt between hepatic vein and portal vein 
within liver via a catheter passed through internal jugular vein. The tract maintained by a 
self expandable metal stent enables decompression of the portal system. Mostly it has been 
used in patients of cirrhosis awaiting liver transplantation. This is a technically difficult 
procedure, costly and needs expertise. The experience in children is small and success rates 
variable between 75-90% (Heyman, 1999).  
8.5.3 Management of mucosal bleeding 
Bleeding or oozing may occur from mucosal lesions associated with congestive gastropathy 
or colopathy due to portal hypertension. Management of gastropathy involves 
neutralization of the gastric acid and stoppage of bleeding from the sites/ lesions. The 
medications used are:  
- Antacids for neutralizing the gastric acid.  
- H2 receptor blockers or proton pump blockers to reduce the gastric acid secretion. 
Duration of use is to be decided based on the nature of mucosal lesion.  
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- Sucralfate forms a protective barrier on the mucosal lesions and prevent contact of 
gastric acid.  
Management of colopathy is difficult and the endoscopic photocoagulation or laser 
coagulation like measures may be helpful. Additionally the beta-blockers are recommended 
for these patients. Recurrent bleeding from portal hypertensive gastropathy and/or 
colopathy usually indicates shunt surgery.  
The flow chart of managing a child with variceal and/or mucosal bleeding is given below.  
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Flow chart: Evaluation and management of upper gastrointestinal bleeding  
8.5.4 Management of acute portal thrombosis 
Spontaneous resolution of recent portal thrombus is rare. Management includes 
conservative medical and surgical interventions. The symptomatic patients with recent 
EHPVO should be started on low molecular weight heparin immediately after detection 
followed by oral anticoagulant therapy. In asymptomatic patients, if detected early, 
anticoagulation should be considered. Dosage of anticoagulation therapy is to be titrated 
with target to maintain international normalized ration (INR) around 2-3. Baveno V 
consensus statement recommends anticoagulation for at least three months, unless long 
term/lifelong therapy is indicated for underlying persistent prothrombotic state (De 
Franchis, 2010). Repeat Doppler is to be done after 3-6 months to check for recanalisation of 
portal vein. In acute thrombosis cases, evidence of infection must be ruled out. If any 
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evidence of infection is there, antibiotic therapy should be given. Advanced minimally 
invasive intervention techniques like direct thrombolysis of portal vein, thrombolysis 
through TIPS are being used. But experience in children is limited.  
8.5.5 Surgical management of EHPVO 
Surgical management of EHPVO includes shunt and non-shunt procedures. The shunt 
procedures aim at reducing portal pressure by diverting the blood from the high-pressure 
portal venous system to the systemic circuit. Shunt surgeries are recommended for EHPVO 
cases not responding to medical and endoscopic management and if associated with 
complications. The indications for shunt surgery include failure of endotherapy to control 
bleeding, presence of gastric or ectopic varices (not amenable to endoscopic management), 
and associated complications like portal biliopathy and large rectal varices. Emergency 
shunt surgery is undertaken now only rarely due to wide availability of endoscopic 
management. The additional indications for shunt surgery include portal biliopathy, severe 
growth failure, massive splenomegaly, hypersplenism, rare blood group, isolated splenic 
vein thrombosis, non- compliance of elective EST/EVL and poor chance of follow up (living 
in remote area). Individualization of each child with EHPVO for shunt surgery is to be done 
considering all the aspects and in consultation with the surgical team.  
Shunts may be non-selective shunts or selective shunts, partial shunts and the more recently 
introduced "Rex shunt"(mesenterico-left portal bypass). 
The non-selective shunts enable complete decompression of the entire portal venous system by 
diverting total portal blood flow away from the liver. These shunts are end to side and side-to-
side portacaval shunts, central lienorenal shunt, end to side mesocaval shunt and large 
diameter interposition portacaval or mesocaval shunts. Although these shunts are effective in 
controlling variceal bleeding, encephalopathy is a concern in patients with poor liver 
functions. Follow up studies have shown shunt patency in 85-98% of children with long term 
survival in >95% cases (Lautz, 2009; Bismuth, 1980; Alvarez, 1983; Gauthier, 1989; Mitra, 1993; 
Prasad, 1994; Orloff, 1994; Superina, 2006; Shariff, 2010). Risk of variceal recurrence and re-
bleed is there in case of shunt blockage. But there is no report of post shunt encephalopathy in 
EHPVO cases. Splenectomy usually done with central lienorenal shunt has not been found to 
be associated with an increased risk of post-splenectomy sepsis (Arora, 2002). 
The selective shunts divert the blood of gastroesophageal-splenic segment and maintain the 
blood flow in mesenteric segment based on the functional classification of portal venous 
system into the splenogastric and mesenteric segments. This enables portal decompression 
with maintenance of hepatopetal portal perfusion, mesenteric venuos pressure and 
hepatotrophic factors. Distal splenorenal shunt, a selective shunt has technical advantage of 
lower chance of post-shunt encephalopathy. The mesoportal bypass (MPB) is a recent 
advancement in shunt restoring mesenteric blood flow to the liver through the Rex venous 
recessus (interposition of a jugular venous allograft between the superior mesenteric vein 
and the intrahepatic left portal vein). This "Rex shunt" restores the physiological hepatopetal 
flow and thereby corrects the liver dysfunction, coagulation parameters and also improves 
the growth potential (Superina, 2006; Mack, 2003; Lautz, 2009). It appears that doing the Rex 
shunt early after diagnosis rather than waiting till complications will be beneficial. But in 
want of clear evidence and experience, there is no consensus on this issue.   
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A subgroup of EHPVO patients may not be suitable for shunt surgery in view of 
complicated vascular anatomy due to extensive thrombosis of the splenoportal axis, prior 
splenectomy or a previously performed but failed shunt procedure. These cases merit non-
surgical management and non-shunt surgical procedures, if required. 
8.5.6 Portosystemic shunt vs endoscopic sclerotherapy 
In a randomized clinical trial by our group in India, we assessed the complications, technical 
problems and rebleeding rates after EST and shunt surgery. Out of the 297 children with 
EHPVO screened, 156 children were randomized into surgical and EST groups (78 children 
in each group). Out of the 78 children randomized into in surgical group, 8 opted out before 
intervention and 28 could not undergo surgery due to technical reason (blockage of splenic 
vein) and hence received EST. Out of the 78 children in EST group, 75 children undergone 
EST (2 opted out before intervention and 1 died). The children were followed up (median 
follow up period 24 months; range: 21-29 months). The pooled incidence of bleeds decreased 
from 0.11/month in pre-intervention period to 0.014/month in post-intervention phase, 
when both the interventions were considered together. The fall in the incidence rate for 
major bleeds was higher (0.05 to 0.002) than that for minor bleeds (0.06 to 0.013). Survival 
analysis showed that among the children who underwent EST, 25% had rebleeding by 16.9 
months after intervention while 50% had rebleeding by 38.4 months. Children who 
underwent surgery had rebleeding by 18.3 months in 25% subjects and less than half of 
these subjects ever rebled. Survivor function at various 6 monthly time intervals during 
follow up was similar between EST and surgery groups. This was true for any kind of re-
bleed; major bleeds and minor bleeds. Relative risk of rebleeding after controlling for period 
of follow up was similar for all types of bleeds. Recurrence of esophageal varices was higher 
in surgery group  compared to the EST group. By 6 months, half of the patients who 
underwent surgical intervention, had recurrence of varices, while the same was observed 
after 24 months in patients who underwent EST. But the risk of rebleeding was not 
influenced by recurrence of varices. Risk of re-bleeding was associated with the age of 
intervention, lesser rebleeding was noticed among children aged >10 years. Hypersplenism 
was observed in 17 children in the EST group compared to 3 children in the surgery group. 
Eight patients in the EST group died compared to 6 patients in the surgery group. It 
appeared from this data that both EST and surgery appear to perform equally well to 
control rebleeding in EHPVO patients. (Arora, 2004).  
8.6 Management of special situations related to EHPVO   
8.6.1 Portal biliopathy 
Symptomatic portal biliopathy is a definite indication for intervention. Primary biliary tract 
surgery is associated with significant morbidity and mortality due to presence of extensive 
collaterals around the bile ducts. Some experts suggest shunt surgery first and if it fails to 
resolve biliary obstruction, then to undertake staged biliary surgery (Chaudhary 1998). 
While others recommend endoscopic management of biliary obstruction first and if 
obstruction persists, then to do the shunt surgery (Khare, 2005). Presence of 
choledocholithiasis without biliary stricture can be managed by endoscopic sphincterotomy 
and stone removal. Presence of stricture may need balloon dilatation and stent placement. In 
cases of endoscopic failure, portosystemic shunt followed by biliary surgery should be 
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undertaken (Khare 2005). There is no clear consensus regarding timing of biliary surgery 
after shunt surgery. The experience in children in this context is limited. Children with 
portal biliopathy undergoing shunt surgery may have normalization of serum 
aminotransferases and gamma glutamyl transpeptidase (GGT) levels within 1 to 6 weeks 
after surgery (Gauthier, 2005). Shunt surgery is indicated in children with symptomatic 
portal biliopathy or even asymptomatic portal biliopathy in presence of growth failure, 
symptomatic hypersplenism or ectopic varices. 
8.6.2 Hypersplenism 
Traditionally, hypersplenism has been treated by splenectomy, open or laparoscopic. In 
view of the risk of overwhelming sepsis in children who are asplenic, the risks and benefits 
must be carefully weighed when splenectomy is being considered. Age of removal of spleen 
is an important consideration; risk of overwhelming sepsis may increase if child is less than 
5 years. Vaccines against pneumococcus, Haemophilus influenza and meningococcus should 
be administered to all children particularly these below 5 years, who are about to undergo 
splenectomy, at least 10 days before splenectomy. Additionally, antibiotic prophylaxis 
(penicillin) is recommended to asplenic children who have not received vaccines. In recent 
times, alternative technique of partial splenic embolisation (PSE) is in use (Dwivedi, 2002). It 
causes ischemic necrosis of a part of spleen and thereby decreases in splenic size and 
hypersplenism. It allows the preservation of adequate splenic tissue and thereby prevents 
the immunological function and protection against overwhelming infection.  
8.6.3 Coagulopathy 
The management of coagulopathy depends on the cause. There is no consensus or clear 
guideline about anticoagulant therapy for prothrombotic conditions in chronic EHPVO. In a 
patient with established chronic EHPVO, anticoagulants are recommended only if there is a 
history of recurrent thrombotic episodes and after shunt surgery (Valla, 2002). 
Anticoagulation therapy is contraindicated in cases with active variceal bleeding and can be 
initiated after variceal obliteration and patient is on beta blocker drug.  
9. Natural history  
The natural course of EHPVO is mainly determined by the age at presentation, presence or 
absence of underlying liver disease, associated systemic diseases. Most patients with 
EHPVO in the absence of liver disease and systemic disease have a relatively benign course. 
Morbidity is mainly related to variceal bleeding, recurrent thrombosis (if associated with 
prothrombotic disorder), symptomatic portal biliopathy, and hypersplenism. In case of 
children with EHPVO, especially in developing countries, nutritional status and growth 
retardation also influence the outcome.  
9.1 Quality of life with EHPVO 
Children with EHPVO suffering in view of repeated episodes of bleeding, undergoing 
diagnostic and therapeutic procedures, associated complications and morbidities, delayed 
growth, may have psychological issues that may impeded their ability and potential in 
physical, emotional, social, academic and other extracurricular segments. A study among 
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Indian children with EHPVO compared the quality of life (QOL) scores in children before 
variceal eradication, after variceal eradication and after surgery with controls. Overall 
children with EHPVO had lower median QOL scores in physical, emotional, social, and 
school functioning health domains compared to controls. Esophageal variceal eradication 
had no significant effect on QOL, but QOL improved after surgery. Most likely surgery 
provided a feeling of cure and reduced further risk and morbidity for both patient and the 
parents and thus resulted improvement in psychological status. Spleen size significantly 
influenced quality of life (QOL) scores and children with massive splenomegaly had poor 
QOL scores as compared with patients with mild and moderate splenomegaly. Total, 
physical, and psychosocial QOL scores were significantly lower in children with growth 
retardation. Both spleen size and growth retardation were independent predictors that affect 
the QOL (Radha Krishna, 2010).  
10. Prognosis 
Unlike patients with chronic liver disease, patients with EHPVO have a good prognosis as 
their liver functions are preserved. Mortality is mainly due to variceal bleeding and it is to 
the tune of 5% (Mowat, 1986). Long term studies after endotherapy have shown almost no 
mortality. Many of these bleeding episodes occurred within the first 4-10 years of variceal 
eradication (Zargar, 2004; Thomas, 2009; Stringer, 1994). The risk of rebleeding reduces with 
increasing age, especially after 10 years of age. With increasing age of survival, children 
with EHPVO are likely to face the longer term consequences in nutrition, mental function 
and portal biliopathy. Long term follow up studies shall be able to answer some of the 
unanswered issues in EHPVO.  
11. Conclusion  
Extrahepatic portal venous obstruction is the commonest cause of portal hypertension and 
variceal bleeding in children. With the availability of diagnostic facilities and effective 
endotherapy, the mortality due to EHPVO related emergencies has become rare. But with 
increasing survival, the sequelae and related morbidities are rising. The evolving surgical 
interventions have raised the hope of averting the long term complications of EHPVO. 
Further generation of evidence on etiology and course of disease including the effect of 
management in children with EHPVO is required, especially in developing countries. At the 
same time availability of trained manpower and facilities for management of acute 
emergencies and advanced surgical interventions will further improve the outcome.  
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